Tumour mutation burden (TMB), defined as the frequency of certain mutations within a tumour’s genes, has been considered as a very promising biomarker for dual ICI with significantly positive predictive value for better PFS and overall survival including patients negative for PD-L1 (29). The gene discussed is CD274; the disease is neoplasm.